TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11996209
Drug: Formulation A
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation A (0.02 mg ethinylestradiol and 0.1 mg levonorgestrel)
Study: 11996209
Drug: Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation B (0.03 mg ethinylestradiol and 0.15 mg levonorgestrel)
Study: 8004298
Drug: Eucapnic Voluntary
Normalized name: Eucardic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eucapnic Voluntary Hyperventilation (EVH) after Methacholine Inhalation Challenge (MIC)
Study: 8004298
Drug: Methacholine Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine Inhalation Challenge (MIC)
Study: 8004298
Drug: Methacholine Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine Inhalation Challenge (MIC) after Eucapnic Voluntary Hyperventilation (EVH)
Study: 2529798
Drug: Loratadine 5
Normalized name: loratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine 5 mg plus pseudoephedrine 120 mg twice a day
Study: 23863328
Drug: Rabeprazole 0.5‐
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 0.5‐ or 1.0‐mg/kg granule formulation for 12 weeks (5 or 10 mg for low-weight cohort; 10 or 20 mg for high-weight cohort)
Study: 23863328
Drug: Rabeprazole 0.5‐
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 0.5‐ or 1.0‐mg/kg granule formulation for 12 weeks
Study: 21823172
Drug: Olanzapine long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine long-acting injection (LAI) (150 mg/2 weeks, 405 mg/4 weeks, or 300 mg/2 weeks)
Study: 21823172
Drug: Oral olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral olanzapine (10, 15, or 20 mg/day)
Study: 21823172
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (LAI and oral olanzapine)
Study: 19635216
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg ketamine infusion under general anesthesia and 0.1 mg/kg ketamine for 24 hours post-surgery
Study: 19635216
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg ketamine infusion under general anesthesia and 0.05 mg/kg ketamine for 24 hours post-surgery
Study: 19635216
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg ketamine infusion under general anesthesia and 0.01 mg/kg ketamine for 24 hours post-surgery
Study: 28440024
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of 2 reduced-diameter implants with locator-analog attachments
Study: 28440024
Drug: Delayed loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loading of 4 reduced-diameter implants with locator-analog attachments
Study: 28440024
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of 2 implants
Study: 25486131
Drug: Extended-release phentermine
Normalized name: phentermine / topiramate Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release phentermine and topiramate
Study: 20068559
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation (1 g tablet after breakfast and 1 g tablet after dinner for 24 weeks)
Study: 16642607
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with routine western medicine (Mannitol, Nifedipine, and Ceftriaxone sodium) for 10 days, starting 9 days after operation.
Study: 16642607
Drug: Routine western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine western medicine (Mannitol, Nifedipine, and Ceftriaxone sodium).
Study: 10493335
Drug: PncD vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PncD vaccine (3 or 10 microg of pneumococcal PS serotypes 6B, 14, 19F, and 23F conjugated to diphtheria toxoid)
Study: 10493335
Drug: PncT vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PncT vaccine (3 or 10 microg of pneumococcal PS serotypes 6B, 14, 19F, and 23F conjugated to tetanus protein)
Study: 10493335
Drug: PncD and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PncD and PncT vaccines
Study: 8905945
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg intravenous (group O)
Study: 7016322
Drug: Melphalan (L-PAM)
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan (L-PAM)
Study: 7016322
Drug: Melphalan (L-PAM)
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan (L-PAM) + 5-FU (PF)
Study: 31183750
Drug: Strength training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength training with daily protein supplementation for 10 weeks
Study: 31579326
Drug: Ultrasound-guided rectus
Normalized name: Sus scrofa rectum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided rectus sheath block with 0.25% ropivacaine (0.5 ml/kg per side)
Study: 31579326
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic infiltration of the surgical field with 0.5% ropivacaine (0.4 ml/kg)
Study: 25467200
Drug: Combined lumbopelvic
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined lumbopelvic motor control and progressive hip strengthening exercise therapy programme
Study: 19196472
Drug: PolyGlycoplex (PGX)
Normalized name: polyglycolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: PolyGlycoplex (PGX) supplementation at a maximum dose of 10 g per day for 21 days
Study: 11206864
Drug: Rizatriptan (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan (5 mg)
Study: 3095111
Drug: Verapamil 3
Normalized name: verapamil 300 mg/24 hours oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 3 X 40 mg X d‐1
Study: 3095111
Drug: Verapamil 3
Normalized name: verapamil 300 mg/24 hours oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 3 X 80 mg X d‐1
Study: 3095111
Drug: Verapamil 3
Normalized name: verapamil 300 mg/24 hours oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 3 X 120 mg X d‐1
Study: 27379911
Drug: Salbutamol inhalation
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol inhalation (5 mg salbutamol sulfate, 1 mL saline + 1 mL salbutamol, nebulized for 10 minutes)
Study: 27379911
Drug: Saline inhalation
Normalized name: Broncho Saline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline inhalation (2 mL nebulized normal saline)
Study: 22436797
Drug: Risperidone 0.5
Normalized name: risperidone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 0.5 mg every 12 hours (n = 51)
Study: 20513750
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy titration to maximal tolerated dose
Study: 18791928
Drug: AHCC (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: AHCC (3.0 g/day for 4 weeks)
Study: 15908270
Drug: Mannitol infusion
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol infusion
Study: 12050274
Drug: Olanzapine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10 mg/d)
Study: 1306421
Drug: Celaskon effervescens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celaskon effervescens Spofa at a dose of 500 mg/day/person
Study: 21566200
Drug: CS‐0777 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS‐0777 0.1 mg
Study: 21566200
Drug: CS‐0777 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS‐0777 0.3 mg
Study: 21566200
Drug: CS‐0777 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS‐0777 1.0 mg
Study: 21566200
Drug: CS‐0777 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS‐0777 2.5 mg
Study: 21566200
Drug: CS‐0777 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS‐0777 (all doses)
Study: 21566200
Drug: CS‐0777 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS‐0777 (2.5 mg)
Study: 1522839
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms of ethinyl estradiol and 1 mg of norgestrel (standard therapy)
Study: 6398430
Drug: Desferrioxamine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desferrioxamine (30 mg/kg body weight/day for 1 week every 3 months)
Study: 6398430
Drug: Hydroxychloroquine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (200 mg twice/wk orally)
Study: 21883097
Drug: Perampanel (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel (up to 4 mg/day, dosed once- or twice-daily) in study 206
Study: 21883097
Drug: Perampanel (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel (up to 12 mg/day, once-daily) in study 208
Study: 18156659
Drug: Protein enriched
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein enriched recovery feeding (218 g protein, 435 g carbohydrate, 79 g fat)
Study: 18156659
Drug: Isocaloric control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric control (34 g protein, 640 g carbohydrate, 79 g fat)
Study: 11898004
Drug: 1% hydrocortisone
Normalized name: HYDROCORTISONE 0.01 g in 1 g TOPICAL OINTMENT [AFASSCO 1% Hydrocortisone]
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1% hydrocortisone acetate ointment
Study: 11898004
Drug: 0.03% tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% tacrolimus ointment and 0.1% tacrolimus ointment
Study: 11898004
Drug: Tacrolimus treatment
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus treatment groups
Study: 10202314
Drug: Metered-dose inhaler
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered-dose inhaler (MDI) with spacer and 1,000 microg salbutamol
Study: 2157469
Drug: nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine 10 mg t.i.d. for six weeks
Study: 7288605
Drug: Naloxone (0.2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.2, 0.4 and 0.8 mg)
Study: 7288605
Drug: Morphine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (5 and 10 mg)
Study: 27093204
Drug: MMC Hydrogel
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMC Hydrogel (0.8 mg MMC with 1cc water and propylene glycol)
Study: 24361227
Drug: Paclitaxel and
Normalized name: paclitaxel and encequidar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel and gemcitabine (PG) chemotherapy
Study: 15241758
Drug: Robotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic therapy for the paretic upper limb (sensorimotor active‐assistive exercise or progressive‐resistive training)
Study: 9696215
Drug: No bromocriptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bromocriptine treatment (Control)
Study: 7808246
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation (6 g.d-1)
Study: 7808246
Drug: Heparin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin administration (2000 units 15 min prior to exercise)
Study: 938185
Drug: Drug plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug plus psychotherapy
Study: 938185
Drug: Milieu therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milieu therapy
Study: 28582809
Drug: Galacto-oligosaccharides (GOS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galacto-oligosaccharides (GOS) 1.0 g twice a day for 12 weeks
Study: 23388530
Drug: Inderal (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inderal (10 mg a day for 10‐20 minutes before meals) and Rozaliak cream (2 times a day)
Study: 23388530
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received a full comprehensive treatment complex including short courses of antibiotics, systemic metronidazole, antihistamines, desensitizing agents, traditional external therapy (Rosamet, 0.75% metronidazole cream)
Study: 23388530
Drug: Inderal and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inderal and Rozaliak cream
Study: 19388883
Drug: Arm-crank exercise
Normalized name: crack willow pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm-crank exercise training (twice weekly for 12 weeks)
Study: 15549277
Drug: Carisoprodol (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carisoprodol (700 mg)
Study: 11544435
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (3.4 g/day)
Study: 8316658
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose radiotherapy (LD‐RT) of 5 x 2 Gy (arm A: 32 patients)
Study: 8316658
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose radiotherapy (HD‐RT) of either 10 x 2 Gy (arm B1; 8 patients) or 5 x 3.5 Gy (arm B2; 20 patients)
Study: 3593901
Drug: Felodipine 15
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine 15 mg
Study: 3593901
Drug: Felodipine 40
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine 40 mg
Study: 3593901
Drug: Felodipine 1
Normalized name: felodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 1 mg (IV)
Study: 3593901
Drug: Felodipine 3
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine 3 mg (IV)
Study: 24828850
Drug: PVB group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVB group (20 mL of 0.5% bupivacaine in the T9‐10 paravertebral space)
Study: 22397953
Drug: tocilizumab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: tocilizumab (4 or 8 mg/kg)
Study: 16685051
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate 10 mg tablets twice a day during hospitalization
Study: 9301400
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate 60 mg kg‐1
Study: 8419695
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no immunomodulatory therapy)
Study: 2943311
Drug: Spironolactone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (200 mg daily)
Study: 30497077
Drug: Classical Turkish
Normalized name: Turkish Licorice Root
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical Turkish music therapy
Study: 26694904
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity shock wave treatment (12 sessions of 1,500 pulses of 0.09 mJ/mm(2) at 120 shock waves per minute)
Study: 26694904
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity shock wave treatment
Study: 26694904
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity shock wave treatment after sham treatment
Study: 25223173
Drug: GnRHa 3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa 3.6 mg by subcutaneous injection starting from the 1st day to the 5th day of menstruation, once per 28 days (Observation 1 group)
Study: 25223173
Drug: GnRHa 3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa 3.6 mg by subcutaneous injection in combination with Wenshen Xiaozheng Decoction (WXD) starting from the 1st day to the 5th day of menstruation, once per 28 days, plus WXD for 7 doses, one cycle per every 28 days (Observation 2 group)
Study: 20578384
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (Tiapride tablets)
Study: 17672075
Drug: Warfarin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin and low-dose ASA
Study: 9825249
Drug: Flupenthixol decanoate
Normalized name: flupenthixol decanoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupenthixol decanoate maintenance therapy
Study: 2553326
Drug: Intravenous nutrition
Normalized name: Intravenous nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nutrition (0.18 g of N + 125 kJ day‐1 kg‐1) for 3 or 7 days before laparotomy
Study: 30415141
Drug: Information package
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information package (brochure, video, personalized phone call reminder) delivered through home visits by specially trained agents
Study: 19444280
Drug: High-dose ARB
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ARB monotherapy (olmesartan medoxomil at 40 mg day(-1))
Study: 19444280
Drug: ARB plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB plus CCB combination therapy (20 mg day(-1) olmesartan with amlodipine or azelnidipine)
Study: 16762125
Drug: Hawthorn extract
Normalized name: hawthorn extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hawthorn extract (1200 mg daily)
Study: 15628632
Drug: Electrotherapy (high-frequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrotherapy (high-frequency transcutaneous and intranasal electric stimulation of nasal muscles for 15 minutes, 3 times a week for 10 weeks)
Study: 9457607
Drug: Vancomycin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (5 mg/kg, twice daily, 1 h infusions)
Study: 3074614
Drug: Flunarizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (10 mg before sleeping)
Study: 3074614
Drug: Betahistine dichlorhydrate
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine dichlorhydrate (8 mg 3 times daily)
Study: 28019091
Drug: Nivolumab (0.3-10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (0.3-10.0 mg/kg)
Study: 25852210
Drug: Composite score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite score of thrombolytic factors (fibrinogen, active and total plasminogen activator inhibitor [PAI]-1)
Study: 25852210
Drug: Composite score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite score of cytokines/adipokines (tumor necrosis factor receptor-1 and -2, active and total PAI-1, IL-6)
Study: 19351624
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg infliximab every 8 weeks (arm A)
Study: 19351624
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg infliximab every 8 weeks (arm B)
Study: 16719029
Drug: Daily multinutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multinutrient energy‐dense oral supplement (6.3 kJ/mL) for six weeks
Study: 16719029
Drug: Tri‐weekly resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri‐weekly resistance training for 12 weeks
Study: 16719029
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (nutrition and resistance training)
Study: 12709775
Drug: Modafinil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (200 mg/day followed by 400 mg/day)
Study: 12709775
Drug: Modafinil using
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil using a taper-down/titrate-up protocol
Study: 8361609
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg quinapril (1 x 20 mg tablet per day)
Study: 8361609
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of nifedipine retard tablets (1 x 20 mg tablet twice daily)
Study: 3740675
Drug: Any alkylating
Normalized name: petroleum alkylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any alkylating agent
Study: 27270480
Drug: NA mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: NA mFOLFOX6 chemotherapy alone (CS group, n = 48)
Study: 27270480
Drug: NA mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: NA mFOLFOX6 chemotherapy with radiation (RCS group, n = 54)
Study: 12895689
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (120 mg/day, n=15)
Study: 31266155
Drug: OLE (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLE (50 mg oleuropein) consumed in capsule form 3 times a day for 1 week
Study: 21736770
Drug: Casein cross-linked
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein cross-linked with transglutaminase (Cas-TG, rigid gel)
Study: 16534456
Drug: 0.9% unpreserved
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% unpreserved unit-dose saline (control)
Study: 12723527
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (n = 17)
Study: 27418381
Drug: ECT plus
Normalized name: Protect Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECT plus medication (venlafaxine plus lithium, four continuation ECT treatments over 1 month)
Study: 27418381
Drug: Medication only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication only (venlafaxine plus lithium over 24 weeks)
Study: 27418381
Drug: ECT plus
Normalized name: Protect Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECT plus medication
Study: 22310055
Drug: 3 or
Normalized name: Cytra-3 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 or 6 months of neo‐adjuvant androgen deprivation therapy (NADT)
Study: 20040034
Drug: Silica coating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silica coating and silanization (n = 8 for each taper angle)
Study: 20040034
Drug: HF acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: HF acid etching and silanization (n = 8 for each taper angle)
Study: 15801991
Drug: Cerivastatin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin (0.2 mg-0.8 mg) at 6 weeks
Study: 15801991
Drug: Cerivastatin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin (0.2 mg-0.8 mg) at 12 weeks
Study: 15801991
Drug: Cerivastatin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin (0.2 mg-0.8 mg) over three time points